Tags

Type your tag names separated by a space and hit enter

Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma.
Int J Radiat Oncol Biol Phys 2006; 66(5):1408-14IJ

Abstract

PURPOSE

Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC.

METHODS AND MATERIALS

Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004. Most patients (72%) presented with Stage III-IV disease. Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy. The major endpoints were local control, overall survival, and complications.

RESULTS

All patients finished the planned dose of radiotherapy. After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences--3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site. The 3-year actuarial rate of local control was 93.1%, regional control 91.4%, freedom from distant metastasis 90.3%, and overall survival 84.9%, respectively. There were no Grade 4 acute or chronic radiation-related complications.

CONCLUSIONS

Fractionated SBRT boost for NPC is technically feasible and provides good local control without any severe complications.

Authors+Show Affiliations

Department of Radiation Oncology, National Cheng Kung University Hospital, Tainan, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Studies
Journal Article

Language

eng

PubMed ID

17126207

Citation

Chen, Helen H W., et al. "Experience in Fractionated Stereotactic Body Radiation Therapy Boost for Newly Diagnosed Nasopharyngeal Carcinoma." International Journal of Radiation Oncology, Biology, Physics, vol. 66, no. 5, 2006, pp. 1408-14.
Chen HH, Tsai ST, Wang MS, et al. Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(5):1408-14.
Chen, H. H., Tsai, S. T., Wang, M. S., Wu, Y. H., Hsueh, W. T., Yang, M. W., ... Lin, J. C. (2006). Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, Physics, 66(5), pp. 1408-14.
Chen HH, et al. Experience in Fractionated Stereotactic Body Radiation Therapy Boost for Newly Diagnosed Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1408-14. PubMed PMID: 17126207.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. AU - Chen,Helen H W, AU - Tsai,Sen-Tien, AU - Wang,Mei-Shu, AU - Wu,Yuan-Hua, AU - Hsueh,Wei-Ting, AU - Yang,Ming-Wei, AU - Yeh,I-Chun, AU - Lin,Jin-Ching, PY - 2006/06/13/received PY - 2006/07/17/revised PY - 2006/07/19/accepted PY - 2006/11/28/pubmed PY - 2007/1/12/medline PY - 2006/11/28/entrez SP - 1408 EP - 14 JF - International journal of radiation oncology, biology, physics JO - Int. J. Radiat. Oncol. Biol. Phys. VL - 66 IS - 5 N2 - PURPOSE: Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC. METHODS AND MATERIALS: Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004. Most patients (72%) presented with Stage III-IV disease. Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy. The major endpoints were local control, overall survival, and complications. RESULTS: All patients finished the planned dose of radiotherapy. After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences--3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site. The 3-year actuarial rate of local control was 93.1%, regional control 91.4%, freedom from distant metastasis 90.3%, and overall survival 84.9%, respectively. There were no Grade 4 acute or chronic radiation-related complications. CONCLUSIONS: Fractionated SBRT boost for NPC is technically feasible and provides good local control without any severe complications. SN - 0360-3016 UR - https://www.unboundmedicine.com/medline/citation/17126207/Experience_in_fractionated_stereotactic_body_radiation_therapy_boost_for_newly_diagnosed_nasopharyngeal_carcinoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(06)02786-6 DB - PRIME DP - Unbound Medicine ER -